Jump to content

Estradiol dipropionate/hydroxyprogesterone caproate

Add links
From Wikipedia, the free encyclopedia
Estradiol dipropionate /
hydroxyprogesterone caproate
Estradiol dipropionate (top) and hydroxy­progesterone caproate (bottom)
Combination of
Estradiol dipropionateEstrogen
Hydroxyprogesterone caproateProgestogen
Clinical data
Trade namesEP Hormone Depot
Other namesEDP/OHPC
Routes of
administration		Intramuscular injection
ATC code
Identifiers
PubChem SID
KEGG

Estradiol dipropionate/hydroxyprogesterone caproate (EDP/OHPC), sold under the brand name EP Hormone Depot, is a combined estrogen–progestogen medication which is used in Japan.[1][2][3][4][5][6][7][8] It is manufactured by Teikoku Zoki Pharmaceutical Co., Tokyo and contains 1 mg/mL estradiol dipropionate and 50 mg/mL hydroxyprogesterone caproate.[2][3][4][5][6][7][8]

See also

[edit]

References

[edit]
  1. ^ "Archived copy". Archived from the original on 2019-04-07. Retrieved 2018-09-17.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ a b Kawamura I, Mizota T, Lacey E, Tanaka Y, Manda T, Shimomura K, Kohsaka M (September 1993). "The estrogenic and antiestrogenic activities of droloxifene in human breast cancers". Jpn. J. Pharmacol. 63 (1): 27–34. doi:10.1254/jjp.63.27. PMID 8271528.
  3. ^ a b Asanuma F, Yamada Y, Kawamura E, Lee K, Kobayashi H, Yamada T, Suzuki T, Kubota T (1998). "Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27". Folia Microbiol. (Praha). 43 (5): 473–4. doi:10.1007/BF02820793. PMID 9821299. S2CID 22732235.
  4. ^ a b Noguchi M, Tajiri K, Taniya T, Kumaki T, Ashikari A, Miyazaki I (1990). "Influence of hormones on proliferation of ER-positive cells and ER-negative cells of human breast cancer (MCF-7)". Oncology. 47 (1): 19–24. doi:10.1159/000226779. PMID 2137212. After the transplantation, each mouse received an intramuscular injection of 0.1 ml EP Hormone Depot consisting of 1 mg/ml 17-β-estradiol dipropionate and 50 mg/ml hydroxyprogesterone caproate every week.
  5. ^ a b Kubota T, Oka S, Utsumi T, Inoue S, Kuzuoka M, Suto A, Arisawa Y, Ishibiki K, Abe O (July 1989). "Human breast carcinoma (ZR-75-1) serially transplanted into nude mice--with reference to estradiol dependency and sensitivity to tamoxifen". Jpn J Surg. 19 (4): 446–51. doi:10.1007/BF02471626. PMID 2810959. S2CID 23267652.
  6. ^ a b Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M (March 1994). "FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity". J. Antibiot. 47 (3): 301–10. doi:10.7164/antibiotics.47.301. PMID 7513682.
  7. ^ a b Hori Y, Abe Y, Nishimura M, Goto T, Okuhara M, Kohsaka M (July 1993). "R1128 substances, novel non-steroidal estrogen-receptor antagonists produced by a Streptomyces. III. Pharmacological properties and antitumor activities". J. Antibiot. 46 (7): 1069–75. doi:10.7164/antibiotics.46.1055. PMID 8360101.
  8. ^ a b Noguchi M, Koyasaki N, Miyazaki I, Mizukami Y (November 1991). "Effects of hormones on tumor growth and immunoreactive insulin-like growth factor-1 of estrogen receptor-positive human breast cancer (MCF-7) transplanted in nude mice". Jpn. J. Cancer Res. 82 (11): 1199–202. doi:10.1111/j.1349-7006.1991.tb01780.x. PMC 5918318. PMID 1752778.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Estradiol_dipropionate/hydroxyprogesterone_caproate&oldid=1214070816"